{
  "id": "breast-cancer-cdk46-main",
  "display_name": "ER+/HER2- MBC (Main)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, 2nd Line (2024–2025)",
  "insight_type": "Utilization Gap",
  "summary": "Dr. Smith prescribes CDK4/6i to 42% of eligible patients, 23% below NCCN guidance. Closing this gap could yield $87,500/year.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Dr. Smith", "value": 42, "gap": -23, "highlight": true },
      { "name": "Dr. Patel", "value": 63, "gap": -2, "highlight": false },
      { "name": "Dr. Lee", "value": 68, "gap": 3, "highlight": false },
      { "name": "Dr. Wang", "value": 73, "gap": 8, "highlight": false }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "financial_impact": {
    "annual_opportunity": "$87,500/year",
    "math": "$87,500/year = 23 patients × $3,800 margin per patient"
  },
  "clinical_impact": {
    "description": "CDK4/6 inhibitors improve survival outcomes and quality of life in ER+/HER2- MBC patients.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+10.2 months",
        "description": "Median progression-free survival benefit"
      },
      {
        "type": "OS",
        "value": "+8.3 months",
        "description": "Median overall survival benefit"
      },
      {
        "type": "ORR",
        "value": "+18%",
        "description": "Improved objective response rate"
      },
      {
        "type": "QoL",
        "value": "+22%",
        "description": "Enhanced quality of life measures"
      },
      {
        "type": "Hosp",
        "value": "-35%",
        "description": "Reduced hospitalization rate"
      }
    ],
    "quantitative": "+10.2 months PFS"
  },
  "peer_comparison": {
    "description": "Dr. Smith prescribes CDK4/6i to 42% of eligible patients, 40% below peer average. Closing this gap could yield $152,000/year.",
    "peer_benchmark": 82,
    "financial_impact": {
      "annual_opportunity": "$152,000/year",
      "math": "$152,000/year = 40 patients × $3,800 margin per patient"
    },
    "action_steps": [
      {
        "text": "Schedule peer-to-peer learning between Dr. Smith and Dr. Wang",
        "icon": "users"
      },
      {
        "text": "Share top-performer best practices with Dr. Smith",
        "icon": "document"
      },
      {
        "text": "Implement peer benchmark monitoring dashboard",
        "icon": "chart"
      },
      {
        "text": "Create provider-specific feedback loops",
        "icon": "clipboard"
      }
    ]
  },
  "weighted_score": 92,
  "action_steps": [
    {
      "text": "Flag patients eligible for CDK4/6i but untreated",
      "icon": "flag"
    },
    {
      "text": "Start provider alignment discussion with Dr. Smith",
      "icon": "users"
    },
    {
      "text": "Share NCCN/CDK4/6i one-pager with practice team",
      "icon": "document"
    },
    {
      "text": "Set monitoring alert for 2L CDK4/6i adherence",
      "icon": "alert"
    }
  ],
  "suggestions": [],
  "drilldowns": [
    {
      "label": "View by Payer Type",
      "cohort": "ER+/HER2- MBC, 2L, by Payer Type",
      "jsonFile": "breast-cancer-cdk46-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Sites",
      "cohort": "ER+/HER2- MBC, 2L, by Site",
      "jsonFile": "breast-cancer-cdk46-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "Variance by Regimen",
      "cohort": "ER+/HER2- MBC, 2L, by Regimen",
      "jsonFile": "breast-cancer-cdk46-by-regimen.json",
      "drilldownLevel": 1
    }
  ]
} 